Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews Signs up China Marketing Partner

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GeneNews today said that it has executed a formal marketing partnership with GeneDiagnostics to sell its ColonSentry test in China.

The agreement follows a term sheet agreement signed between the partners last month. Financial terms of the agreement have not been disclosed.

The agreement provides GeneDiagnostics with non-exclusive rights to market and sell the ColonSentry test in Shanghai and in the provinces of Zhejiang and Jiangsu. GeneDiagnostics expects to begin selling the test in those areas in the fourth quarter of this year.

ColonSentry is Toronto-based GeneNews' first product and has been launched in Canada, with a commercial introduction expected in the US later this year. It is a blood-based test that is used to pre-screen and assess an individual's current risk for colorectal cancer.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.